Compare Globus Medical Inc. Class A Common Stock (GMED) vs Venture Global Inc. Class A common stock (VG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Venture Global Inc. Class A common stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Venture Global Inc. Class A common stock trades at $13.23 (market cap $34.60B). The key difference: Venture Global Inc. Class A common stock is far larger — about 3.4× Globus Medical Inc. Class A Common Stock's market cap, and Venture Global Inc. Class A common stock pays a 1.16% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Venture Global Inc. Class A common stock for 1 Days on average.
| GMED | VG | |
|---|---|---|
Market Cap | $10.25B | $34.60B |
Volume | 1,108,124 | 11,731,839 |
Sector | Health | Energy |
52-Week High | $96.82 | $17.53 |
52-Week Low | $58.33 | $5.92 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $9.76B | $73.99B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VG trades at $13.84, up 5.41% today, with a bearish technical signal but strong fundamentals including a 21.24% net income margin and 48.13% ROE. Recent earnings have consistently beaten estimates, and the company is expanding LNG capacity to 85 MTPA by 2029, supported by long-term supply deals like the 20-year agreement with ConocoPhillips announced on October 1, 2026.
The stock offers value with a P/E of 10.52 and consensus price target of $16.13, but faces risks from high short interest and negative net cash flow in 2025. Analyst sentiment is bullish with 58% buy ratings, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Venture Global Inc. Class A common stock
Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →
